clinical assessment. Penetration is good in synovial fluid, bone, gall bladder and bile. These cases illustrate that significant interindividual variability exists among patients receiving linezolid, and a direct way to optimize drug exposure is with TDM.Cattaneo et al stated that renal function, age, weight, and concurrent medications can significantly affect the pharmacokinetics of linezolid.TDM for linezolid is important in patients with serious infections due to the high interindividual variability. Accordingly, the recommended dose of linezolid for infants and children is 10 mg/kg every 8–12 h. However, no clinical studies of linezolid at a dose of 10 mg/kg administered more frequently than every 12 h have been conducted in pediatric patients to date [IV linezolid should be infused over a period of 30–120 min.
One hundred and sixty patients received the drug because of intolerance to vancomycin (131 patients) or lack of clinical response (29 patients).
Both groups of patients received aztreonam until the presence of Gram‐negatives was excluded [In patients whom it was possible to evaluate, clinical cure rates (71 of 107 [66.4%] for linezolid vs. 62 of 91 [68.1%] for vancomycin) and micro‐biological success rates (36 of 53 [67.9%] vs. 28 of 39 [71.8%], respectively) were equivalent between both treatment groups. Apart from these studies, one report of vertebral osteomyelitis successfully treated with linezolid in a patient receiving hemodialysis has been published. At steady state, 30% of linezolid is excreted unchanged in the urine.
for clinical efficacy, safety and tolerability.
The patient was treated with the recommended oral dosage of linezolid, 600 mg q12h for a total of 8 weeks. Frozen-section analysis as well as the final pathology report revealed synovitis with 2 microabscesses and scattered polymorphonuclear leukocytes (∼20 cells per high-power field). Numerous variables contribute to clinical outcomes, and one commonly overlooked is interpatient variability. It may be preferred over vancomycin because of the possibility of switching to the oral form and to avoid emergence of vancomycin‐resistant enterococci.The efficacy of linezolid in the treatment of different infections caused by Gram‐positive bacteria has been evaluated in phase II or III clinical trials.As of January 2000, 671 patients in the USA had received linezolid as part of a noncomparative, nonblind phase II compassionate use program because of intolerance or clinical failure to standard therapy [A randomized, multicenter, nonblind phase III clinical trial compared the efficacy of linezolid (240 patients) and vancomycin (220 patients) as treatment for infections caused by methicillin‐resistant The inclusion criterion was to be a hospitalized patient with bacteremia, SSTIs, urinary tract infections (UTIs), right‐sided endocarditis or pneumonia caused by MRSS.
diabetic foot (18%), sternal wound (14.5%) and vertebral Informed consent osteomyelitis (15%).
Antimicrobial therapy was modified to linezolid 600 mg IV q12h and piperacillin‐tazobactam 4.5 g IV q6h administered over 3 hours. Non‐renal clearance accounted for 65% of its excretion.
He had decreased range of motion of the left hip and experienced pain on movement. Despite similarities in age and renal function, the first patient experienced an elevated trough concentration. Fourteen months after the completion of therapy, the patient had experienced no recurrent hip pain and was ambulating with the assistance of 2 canes.